By Josh White
Date: Monday 31 Mar 2025
(Sharecast News) - Bioventix reported a marginal rise in revenue for the six months ended 31 December on Monday, with profit before tax dipping slightly due to higher research and development expenditure.
By Iain Gilbert
Date: Thursday 31 Oct 2024
(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
By Josh White
Date: Monday 28 Oct 2024
(Sharecast News) - BioVentix, a UK-based developer of high-affinity monoclonal antibodies for clinical diagnostics, reported a 6% improvement in full-year revenue on Monday, to £13.6m, up from £12.82m in the prior year.
Currency | UK Pounds |
Share Price | 2,525.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 4,325.00p |
52 Week Low | 2,300.00p |
Volume | 3,739 |
Shares Issued | 5.22m |
Market Cap | £131.93m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 10-Apr-25 | 07-Nov-24 |
Paid | 25-Apr-25 | 21-Nov-24 |
Amount | 70.00p | 87.00p |
Time | Volume / Share Price |
15:43 | 200 @ 2,550.00p |
15:44 | 100 @ 2,520.00p |
15:06 | 55 @ 2,538.00p |
14:40 | 188 @ 2,500.00p |
14:08 | 20 @ 2,540.00p |
CEO | Peter John Harrison |
Chair | Ian James Nicholson |
CFO | Bruce Hiscock |
You are here: research